{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:48:31Z","timestamp":1782823711276,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejpb.2026.115070","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T01:56:32Z","timestamp":1775181392000},"page":"115070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Recombinant human hyaluronidase PH20 facilitates rapid subcutaneous infusion: two randomized, double-blind, self-controlled phase III clinical trials"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4918-9126","authenticated-orcid":false,"given":"Haiping","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115070_b0005","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: An overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs."},{"key":"10.1016\/j.ejpb.2026.115070_b0010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/cpt.3179","article-title":"Subcutaneous biologics: Clinical pharmacology and drug development","volume":"115","author":"Ait-Oudhia","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.115070_b0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/17425247.4.4.427","article-title":"Recombinant human hyaluronidase (rHuPH20): An enabling platform for subcutaneous drug and fluid administration","volume":"4","author":"Frost","year":"2007","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2026.115070_b0020","unstructured":"Amgen Inc. Highlights of Prescribing Information. RePATHA (evolcumab) injection, for subcutaneous use. . https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Repatha\/repatha_pi_hcp_english_current.pdf, 2025 (accessed 18 March 2026)."},{"key":"10.1016\/j.ejpb.2026.115070_b0025","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2023.2252999","article-title":"Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig model","volume":"30","author":"Connor","year":"2023","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2026.115070_b0030","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/cpt.2385","article-title":"Safety, tolerability, and pharmacokinetics of high-volume subcutaneous crenezumab, with and without recombinant human hyaluronidase in healthy volunteers","volume":"110","author":"Dolton","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.115070_b0035","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jconrel.2006.05.027","article-title":"A recombinant human enzyme for enhanced interstitial transport of therapeutics","volume":"114","author":"Bookbinder","year":"2006","journal-title":"J. Control Release."},{"key":"10.1016\/j.ejpb.2026.115070_b0040","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/imt-2017-0092","article-title":"Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases","volume":"9","author":"Wasserman","year":"2017","journal-title":"Immunotherapy."},{"key":"10.1016\/j.ejpb.2026.115070_b0045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/5584_2016_54","article-title":"Hyaluronidase and Chondroitinase","volume":"925","author":"Wang","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejpb.2026.115070_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2022.108018","article-title":"Insights into the source, mechanism and biotechnological applications of hyaluronidases","volume":"60","author":"Zhang","year":"2022","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ejpb.2026.115070_b0055","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1208\/s12248-022-00757-3","article-title":"Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration","volume":"24","author":"Printz","year":"2022","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2026.115070_b0060","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/01.NAN.0000292572.70387.17","article-title":"Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial","volume":"30","author":"Yocum","year":"2007","journal-title":"J. Infus. Nurs."},{"key":"10.1016\/j.ejpb.2026.115070_b0065","unstructured":"FDA, Labels for Biologic License Application 021859. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=021859, 2005 (accessed 18 March 2026)."},{"key":"10.1016\/j.ejpb.2026.115070_b0070","unstructured":"FDA, Highlights of Prescribing Information. HYLENEX recombinant (hyaluronidase human injection) for infiltration use, for interstitial use, for intramuscular use, for intraocular use, for peribulbar use, retrobulbar use, for soft tissue use and for subcutaneous use. https:\/\/nctr-crs.fda.gov\/fdalabel\/services\/spl\/set-ids\/3023cc56-ed4b-4e87-b3a1-81b20943f658\/spl-doc?hl=hyaluronidase, 2024 (accessed 18 March 2026)."},{"key":"10.1016\/j.ejpb.2026.115070_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.02.069","article-title":"An industry perspective on hyaluronidase co-formulated biopharmaceutics","volume":"381","author":"Guo","year":"2025","journal-title":"J. Control Release."},{"key":"10.1016\/j.ejpb.2026.115070_b0080","unstructured":"EMA, Herceptin-H-C-278-X-0060: EPAR-Assessment Report-Extension. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/herceptin-h-c-278-x-0060-epar-assessment-report-extension_en.pdf, 2013 (accessed 18 March 2026)."},{"key":"10.1016\/j.ejpb.2026.115070_b0085","first-page":"95","article-title":"A phase I clinical study to evaluate rapid, high-volume, subcutaneous auto-injector tolerability with recombinant human hyaluronidase, Drug Deliv","volume":"16","author":"Kang","year":"2026","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejpb.2026.115070_b0090","unstructured":"FDA, Labels for Biologic License Application 761064. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761064, 2017 (accessed 18 March 2026)."},{"key":"10.1016\/j.ejpb.2026.115070_b0095","unstructured":"FDA, Labels for Biologic License Application 761106. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761106,2019 (accessed 18 March 2026)."},{"key":"10.1016\/j.ejpb.2026.115070_b0100","unstructured":"FDA, Labels for Biologic License Application 761145. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761145, 2020 (accessed 18 March 2026)."},{"key":"10.1016\/j.ejpb.2026.115070_b0105","unstructured":"FDA, Labels for Biologic License Application 761170. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761170, 2020 (accessed 18 March 2026)."},{"key":"10.1016\/j.ejpb.2026.115070_b0110","unstructured":"FDA, Labels for Biologic License Application 761304. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761304, 2023 (accessed 18 March 2026)."},{"key":"10.1016\/j.ejpb.2026.115070_b0115","unstructured":"FDA, Labels for Biologic License Application 761347. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761347, 2024 (accessed 18 March 2026)."},{"key":"10.1016\/j.ejpb.2026.115070_b0120","unstructured":"FDA, Labels for Biologic License Application 761371. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761371, 2024 (accessed 18 March 2026)."},{"key":"10.1016\/j.ejpb.2026.115070_b0125","unstructured":"FDA, Labels for Biologic License Application 761381. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761381, 2024 (accessed 18 March 2026)."},{"key":"10.1016\/j.ejpb.2026.115070_b0130","unstructured":"FDA, HYQVIA. https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/hyqvia, 2025 (accessed 18 March 2026)."},{"key":"10.1016\/j.ejpb.2026.115070_b0135","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/10717544.2018.1551442","article-title":"ENHANZE\u00aedrug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20","volume":"26","author":"Locke","year":"2019","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2026.115070_b0140","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jpainsymman.2009.03.010","article-title":"The INFUSE-Morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteers","volume":"38","author":"Thomas","year":"2009","journal-title":"J. pain symptom manage."},{"key":"10.1016\/j.ejpb.2026.115070_b0145","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/dia.2009.0013","article-title":"Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase","volume":"11","author":"Vaughn","year":"2009","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.ejpb.2026.115070_b0150","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1089\/dia.2011.0115","article-title":"Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers","volume":"13","author":"Morrow","year":"2011","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.ejpb.2026.115070_b0155","doi-asserted-by":"crossref","unstructured":"R.L. Wasserman, I. Melamed, M.R. Stein, S. Gupta, J. Puck, et al, Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency, J. Allergy Clin. Immunol. 130 (2012) 951-7.e11, doi: 10.1016\/j.jaci.2012.06.021.","DOI":"10.1016\/j.jaci.2012.06.021"},{"key":"10.1016\/j.ejpb.2026.115070_b0160","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1089\/jpm.2007.0126","article-title":"von Gunten Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study","volume":"10","author":"Thomas","year":"2007","journal-title":"J. Palliat. Med."},{"key":"10.1016\/j.ejpb.2026.115070_b0165","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/jns.12672","article-title":"Long-term safety and tolerability of hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE-CIDP 3 trial","volume":"29","author":"Hadden","year":"2024","journal-title":"J. Peripher. Nerv. Syst."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126000913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126000913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:29:36Z","timestamp":1782822576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126000913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"alternative-id":["S0939641126000913"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115070","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant human hyaluronidase PH20 facilitates rapid subcutaneous infusion: two randomized, double-blind, self-controlled phase III clinical trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115070"}}